leqembi news - Search News

Seeking Alpha on MSN · 11h

Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn’t expect Biogen (BIIB) to return to growth until 2026,

Business Insider · 12h

Needham downgrades Biogen to Hold on lack of share catalysts

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares

ca.investing.com on MSN · 10h

Needham downgrades Biogen on slow growth of Alzheimer's drug

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months. The brokerage stated that Leqembi’s sales

Worldcrunch on MSN11h

Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

10h

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

4don MSN

European committee takes a second look at Alzheimer’s drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

GlobalData on MSN4d

EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

EU Backs Leqembi: A Breakthrough in Alzheimer's Treatment

The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a ...

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results